Background: Liraglutide improved metabolic derangement in type 2 diabetes (T2D). The study aimed to measure changes in glycemic and metabolic parameters after addition of liraglutide in obese insulin-resistant T2D patients
Methods: liraglutide was added to 45 Adult T2D patients, who were on 4 regimens as follows:18 on Sulphonylurea(SU), 9 on SU and Basal insulin, 3 on basal insulin and 15 on multiple daily insulin injections(MDIs). Five patients had history of cardiovascular diseases (CVD).The cohort was followed for 6 months and Liraglutide dose 0.6 escalated to 1.2 mg based on patient tolerance. Glycemic, metabolic and anthropometric parameters were measured every 3 months
Results: Mean age and T2D duration were 51.5±12.9 and 11.6±1.6 years, respectively. Body weight significantly reduced from 98.7kg to 96.0kg, p< 0.001, with a mean difference of 3.39kg ± 5.6kg. Systolic blood pressure reduced from 131.7mmHg to 126.6mmHg (Diff. 6.1mmHg), p = 0.015 while Diastolic blood pressure reduced from 73.3mmHg to 68.6mmHg (Diff. 4.7mmHg), p = 0.026. Most HbA1c reduction observed in the liraglutide 1.2 mg dose group with changes from 9.8% to 8.2% (Diff. 1.6%); and also the most weight reduction observed in the 1.2 mg liraglutide dose group with changes from 103.3kg to 99.7kg (Diff. 3.6kg) compared to 0.6 and 1.8 mg dose groups. HbA1c reduction was largest in MDIs group from 10.2 to 8.6% (Diff. 1.6%). Meanwhile, the most weight reduction noticed in the treatment group on SU and Basal insulin from 97.2kg to 92.8kg (Diff. 4.4kg). Interestingly, patients with CVD had improved HbA1c with changes from 10.62% to 9.77% (Diff. 0.85%) and weight from 86.96kg to 85.72kg (Diff. 1.24kg) without evident hypoglycemia.
Conclusions: Addition of liraglutide to different T2D therapeutic regimen in obese Insulin- resistant patients showed significant improvement in HbA1c, weight, and Blood pressure. These results support the use in primary care clinics.
T. Alharbi: None. A. Tourkmani: None. S. Altwaijri: None. M. Kofi: None.